Literature DB >> 10206550

Bicyclo[3.2.1]octanes: synthesis and inhibition of binding at the dopamine and serotonin transporters.

P C Meltzer1, P Blundell, Z Chen, Y F Yong, B K Madras.   

Abstract

Herein we report the synthesis of a series of bicyclo[3.2.1]octanes and their binding characteristics at the dopamine and serotonin transporters. The data confirm that a heteroatom at position 8 of the tropane nucleus is not a prerequisite for binding since the bicyclo[3.2.1]octanes prove potent inhibitors of both transporters. Therefore the three-dimensional topology of the ligand may be more important than specific functionality with respect to stereospecific binding at the acceptor site.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10206550     DOI: 10.1016/s0960-894x(99)00098-0

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.

Authors:  Lokman Torun; Bertha K Madras; Peter C Meltzer
Journal:  Bioorg Med Chem       Date:  2012-02-08       Impact factor: 3.641

2.  Conformational preferences of the potent dopamine reuptake blocker BTCP and its analogs and their incorporation into a pharmacophore model.

Authors:  M Froimowitz; K M Wu; J Rodrigo; C George
Journal:  J Comput Aided Mol Des       Date:  2000-02       Impact factor: 3.686

3.  Synthesis of 8-thiabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.

Authors:  Duy-Phong Pham-Huu; Jeffrey R Deschamps; Shanghao Liu; Bertha K Madras; Peter C Meltzer
Journal:  Bioorg Med Chem       Date:  2006-10-27       Impact factor: 3.641

4.  Synthesis of highly functionalised enantiopure bicyclo[3.2.1]- octane systems from carvone.

Authors:  Antonio Abad; Consuelo Agulló; Ana C Cuñat; Ignacio de Alfonso; Ismael Navarro; Noelia Vera
Journal:  Molecules       Date:  2004-04-30       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.